- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01693601
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (PRIME)
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME STUDY) - Phase I/II Study of Combination Oral JAK2 Tyrosine Kinase Inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) Therapy in Patients With Myelofibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients aged ≥ 18 years old
- Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
Intermediate-2 and higher by IWG-MRT Post PV/ET MF and PMF patients either in
- Chronic Phase (MF-CP)
- Accelerated Phase (MF-AP)
Patients must meet the following laboratory criteria:
- ANC ≥ .750 x 109/L
- Platelets ≥ 75 x 109/L
- Creatinine ≤ 1.5 x ULN,
- AST and ALT ≤ 2.5 x ULN
- Serum bilirubin ≤ 1.5 x ULN (unless Gilbert's syndrome and evidence of hemolysis)
- Serum potassium ≥ LLN
- Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN,
- Serum magnesium ≥ LLN
- Serum phosphorus ≥ LLN
- Free T4 within normal limits
- ECOG Performance Status of ≤ 3
- Any prior therapy with JAK2-TKI, hypomethylating agents, HDACI, mTORi, or iMiDs is allowed as long as it is greater than 3 weeks since last dose of administration and in the case of a JAK2-TKI or HDACI that discontinuation was not due to non-hematologic drug toxicity. An exception to this criteria are patients currently on at least 10mg BID of ruxolitinib for greater than 3 months and who have not shown an optimal response (i.e. without 50% reduction in palpable splenomegaly or 50% reduction in symptom burden). With a reduction of ruxolitinib to 10mg BID these patients may enter onto the study without stopping ruxolitinib
Exclusion Criteria:
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANOBINOSTAT treatment.
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- With permanent cardiac pacemaker
- Resting bradycardia defined as <50 beats per minute
- QTcF >450 msec on screening ECG
- Complete Left bundle branch block, bifascicular block
- Any clinically significant ST segment and/or T-wave abnormalities
- Presence of unstable atrial fibrillation (ventricular response rate >100 bpm). Patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria.
- Symptomatic congestive heart failure (NYHA class III-IV)
- Impairment of GI function or GI disease that may significantly alter the absorption of PANOBINOSTAT or RUXOLITINIB
- Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol
- Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug
- Concomitant use of CYP3A4 inhibitors
- Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies.
- Chemotherapy within 3 weeks prior to screening are excluded (other than hydroxyurea at stable doses and will be discontinued 24 hours prior to starting study drug).
- Patients with an active bleeding tendency or are receiving any treatment with therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Patients will be allowed to enter study on aspirin at doses of 81mg/d.
- Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- Women who are pregnant or breast-feeding or women of childbearing potential (WOCBP) not using an effective method of birth control. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test within 24hrs of receiving the first dose of study medication.
- Male patients whose sexual partners are WOCBP not using effective birth control
- Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
- Disease associated with secondary MF such as metastatic carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease or acute leukemia (including M7 disease or acute panmyelosis with MF)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Panobinostat and Ruxolitinib
Combination of Panobinostat and Ruxolitinib
|
PO TIW QOW or PO TIW QW
Other Names:
PO BID x 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients That Achieve Stable Disease or Clinical Improvement
Time Frame: at least 6 months
|
Number of patients that have either stable disease or clinical improvement treatment response as defined by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Stable disease (SD) - response that is not complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, or progressive disease. Clinical improvement (CI) - a response in anemia, splenomegaly, or MF-SB that is not associated with progressive splenomegaly or increase in severity of anemia, thrombocytopenia, or neutropenia. |
at least 6 months
|
Number of Participants Who Experienced Dose-Limiting (DLTs)
Time Frame: up to cycle 6, day 29
|
Panobinostat related adverse events requiring dose reduction or discontinuing prior to Cycle 6, Day 29 (C6D29)
|
up to cycle 6, day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Spleen Volume
Time Frame: Baseline and Cycle 6, Day 29
|
Percent change in spleen volume at C6D29 as compared to baseline
|
Baseline and Cycle 6, Day 29
|
Percent Change in Spleen Size for Responders and Non-responders
Time Frame: Cycle 6, Day 29
|
Percent change in spleen length size by palpation at cycle 6, day 29 (C6D29) from baseline
|
Cycle 6, Day 29
|
Percent Change in Spleen Length
Time Frame: Cycle 6, Day 29
|
Percent change in spleen length at C6D29
|
Cycle 6, Day 29
|
Number of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)
Time Frame: baseline, C1D1 and Cycle 6 Day 29
|
Symptom responders defined as having a percent change in MPN-SAF score from Screening/C1D1 to C6D29 of more than 50%.MPN-SAF is an 18-item instrument.
Each item score 0-10 averaged, total scale from0-10, with higher score indicating more symptoms.
|
baseline, C1D1 and Cycle 6 Day 29
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 12-1225
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelofibrosis
-
Assaf-Harofeh Medical CenterUnknownMyelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ETIsrael
-
Centre Hospitalier Annecy GenevoisCompleted
-
AbbVieRecruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
-
AbbVieTerminatedMyelofibrosis (MF)United States, Korea, Republic of, South Africa
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingModerate and High Risk MyelofibrosisChina
-
Telios Pharma, Inc.RecruitingPrimary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET MyelofibrosisSpain, United States, France, Poland, Italy, Germany
Clinical Trials on Panobinostat
-
Centre Leon BerardCompleted
-
SCRI Development Innovations, LLCNovartis; Onyx Therapeutics, Inc.CompletedMultiple MyelomaUnited States
-
Dana-Farber Cancer InstituteNovartis; Brigham and Women's HospitalCompletedWaldenstrom's MacroglobulinemiaUnited States
-
NovartisCompletedCutaneous T-Cell Lymphoma | TumorsJapan
-
University of Wisconsin, MadisonNovartis PharmaceuticalsTerminated
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedGraft-Versus-Host DiseaseUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Solid TumorsSwitzerland, Netherlands, United States, United Kingdom
-
Duke UniversityNovartisWithdrawn
-
Novartis PharmaceuticalsCompletedAcute Myelogenous Leukemia | Refractory LeukemiaBelgium, Korea, Republic of, Turkey, Germany, Australia, France, Switzerland, United Kingdom, Spain, Italy, Peru, United States
-
Peter MacCallum Cancer Centre, AustraliaCompletedMultiple Myeloma | Nodal Lymphoma | Lymphoma With Cutaneous Involvement | Lymphoma in Leukemic Phase | Marrow Involvement With LymphomaAustralia